- About Pancreatic Cancer
- Get Support
Caregivers
- Get Involved
- Events
- More
2019-03-28
2021-06-03
2025-12-31
420
NCT04241367
National Cancer Center, Korea
National Cancer Center, Korea
OBSERVATIONAL
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients. * Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples. * Correlation analysis of KRAS mutation results with clinical data. Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel. * Gene panel composition for pancreatic cancer therapeutic target determination and monitoring. * A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients. * Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
| Study Registration Dates | Results Reporting Dates | Study Record Updates |
|---|---|---|
2020-01-22 | N/A | 2025-06-16 |
2020-01-22 | N/A | 2025-06-19 |
2020-01-27 | N/A | 2025-06 |
This section provides details of the study plan, including how the study is designed and what the study is measuring.
Primary Purpose:
N/A
Allocation:
N/A
Interventional Model:
N/A
Masking:
N/A
Arms and Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|
| Primary Outcome Measures | Measure Description | Time Frame |
|---|---|---|
| Clinical applicability of KRAS mutations | Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients. | Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months |
| Discovery of biomarkers through ctDNA panel | Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel. | Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months |
| Secondary Outcome Measures | Measure Description | Time Frame |
|---|
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.
Ages Eligible for Study:
ALL
Sexes Eligible for Study:
Accepts Healthy Volunteers:
This is where you will find people and organizations involved with this study.
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
